SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABS · Delayed Price · USD
5.25
-0.71 (-11.91%)
At close: Jan 26, 2022 4:00 PM
5.24
-0.01 (-0.25%)
After-hours:Jan 26, 2022 4:00 PM EST

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year20202019
Revenue
55.243.44
Revenue Growth (YoY)
1504.91%-
Gross Profit
55.243.44
Selling, General & Admin
6.774.1
Research & Development
27.918.02
Operating Expenses
34.6812.12
Operating Income
20.56-8.67
Interest Expense / Income
0.470.43
Other Expense / Income
-0.03-0.12
Pretax Income
20.12-8.99
Net Income
20.12-8.99
Net Income Common
20.12-8.99
Shares Outstanding (Basic)
3535
Shares Outstanding (Diluted)
5835
Shares Change
64.84%-
EPS (Basic)
0.37-0.26
EPS (Diluted)
0.35-0.26
Free Cash Flow Per Share
-0.08-0.28
Gross Margin
100.00%100.00%
Operating Margin
37.22%-252.01%
Profit Margin
36.42%-261.09%
Free Cash Flow Margin
-4.92%-285.41%
EBITDA
21.14-8.23
EBITDA Margin
38.26%-239.25%
EBIT
20.59-8.56
EBIT Margin
37.27%-248.64%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).